jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

CD23

Immunity
image

Report in 72Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Flow cytometry panel of immune cell surface markers.

₹2,738₹3,911

30% OFF

CD23 Test Information Guide

  • Why is it done?
    • CD23 is a flow cytometry marker used to identify and classify B-cell lymphomas and leukemias
    • Helps differentiate chronic lymphocytic leukemia (CLL) from marginal zone lymphoma and lymphoplasmacytic lymphoma
    • Assists in diagnosing and monitoring patients with suspected lymphoproliferative disorders
    • Used when patients present with abnormal lymphocyte counts, lymphadenopathy, or splenomegaly
    • Performed during initial diagnosis and throughout treatment monitoring of hematologic malignancies
  • Normal Range
    • Normal Result: CD23 is typically absent or minimally expressed on normal mature B lymphocytes in peripheral blood
    • Percentage Range: CD23+ B cells typically comprise less than 30% of total B lymphocytes in healthy individuals
    • Absolute Count: Generally less than 500 cells/μL (varies by laboratory)
    • Interpretation: Negative (absent) = Normal; Positive (present) = May indicate lymphoproliferative disorder
    • Units of Measurement: Percentage (%), cells/μL, or fluorescence intensity reported as mean channel fluorescence (MCF)
  • Interpretation
    • CD23 Positive (Increased Expression): Suggests presence of lymphoproliferative disorder, particularly CLL, follicular lymphoma, or other B-cell malignancies; Used with CD5 positivity to identify CLL (CD5+/CD23+ phenotype)
    • CD23 Negative (Absent/Low Expression): May indicate marginal zone lymphoma, mantle cell lymphoma (CD5+/CD23-), or reactive lymphocytosis; Generally reassuring in most clinical contexts
    • CD5+/CD23+ Pattern: Highly specific for CLL; considered diagnostic in appropriate clinical context
    • CD5+/CD23- Pattern: Characteristic of mantle cell lymphoma; important for treatment planning and prognosis
    • Factors Affecting Results: Sample quality, time from collection to analysis, recent immunotherapy, previous chemotherapy, specimen hemolysis, or improper storage may affect accuracy
    • Clinical Significance: CD23 expression patterns are crucial for accurate lymphoma classification and determining appropriate treatment strategies; results must be interpreted within complete immunophenotypic panel and clinical context
  • Associated Organs
    • Primary Organ System: Lymphatic system and bone marrow; specifically involves B lymphocytes
    • Commonly Associated Conditions: Chronic lymphocytic leukemia (CLL), follicular lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma (SLL), marginal zone lymphomas, and other B-cell non-Hodgkin lymphomas
    • Diseases This Test Helps Diagnose: Chronic lymphocytic leukemia, lymphomas, immunoproliferative disorders, and distinguishing between reactive and clonal B-cell expansions
    • Related Lymphoid Tissues: Lymph nodes, bone marrow, spleen, and other lymphoid organs may be affected by conditions detected through CD23 testing
    • Potential Complications: Untreated lymphoproliferative disorders may progress to advanced disease, causing organ dysfunction, cytopenias, infections, and life-threatening complications; early diagnosis improves treatment outcomes
  • Follow-up Tests
    • Recommended Additional Tests: Complete flow cytometry panel including CD5, CD19, CD20, CD79b, and surface immunoglobulin testing
    • Further Investigations: Bone marrow biopsy and aspirate, cytochemical stains, genetic testing (FISH panel, TP53 mutation analysis, IGHV mutation status), LDH level, and CT imaging for staging
    • Monitoring Frequency: For diagnosed CLL: every 3-6 months during active monitoring; more frequently during treatment; less frequently during stable watch-and-wait approach
    • Complementary Tests: Complete blood count (CBC) with differential, comprehensive metabolic panel, LDH, immunoglobulin levels, and B2-microglobulin
    • Post-Treatment Monitoring: Repeat flow cytometry to assess treatment response and achieve minimal residual disease (MRD) status; intervals determined by treating physician
  • Fasting Required?
    • Fasting Required: No
    • Dietary Restrictions: None; patient may eat and drink normally before the test
    • Medications: Continue all current medications as prescribed unless specifically instructed otherwise by your physician
    • Patient Preparation: Arrive with adequate hydration; bring insurance card and identification; inform phlebotomist of any recent immunotherapy, chemotherapy, or hematopoietic stem cell transplant
    • Sample Collection: Peripheral blood sample collected in EDTA (lavender top) tube; should be processed within 24-48 hours for optimal results
    • Special Instructions: No special preparation needed; test can be performed at any time of day

How our test process works!

customers
customers